Last reviewed · How we verify
VAX161C vaccine
At a glance
| Generic name | VAX161C vaccine |
|---|---|
| Sponsor | VaxInnate Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAX161C vaccine CI brief — competitive landscape report
- VAX161C vaccine updates RSS · CI watch RSS
- VaxInnate Corporation portfolio CI